Sotorasib Shows Intracranial Activity in Patients with KRAS G12C- Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases

Kira-Lee Koster; Christina Appenzeller; Arno Lauber; Martin Früh; Sabine Schmid

doi:10.1159/000525341

Sotorasib Shows Intracranial Activity in Patients with KRAS G12C- Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases

Case Rep Oncol. 2022 Aug 26;15(2):720-725. doi: 10.1159/000525341. eCollection 2022 May-Aug.

Authors

Kira-Lee Koster¹, Christina Appenzeller¹, Arno Lauber², Martin Früh^{1

3}, Sabine Schmid^{1

3}

Affiliations

¹ Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
² Department of Radiology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
³ Department of Oncology, University of Bern, Bern, Switzerland.

Abstract

Treatment with sotorasib has shown intracranial complete responses and continued intracranial stabilization in KRAS G12C-mutated non-small-cell lung carcinoma (NSCLC) patients with previously treated, stable brain metastases in a post hoc analysis of the ongoing CodeBreaK 100 trial. We present the case of a patient with KRAS G12C-mutant adenocarcinoma of the lung with active untreated brain metastases with a nearly complete intracranial response only 6 weeks after start of sotorasib illustrating the benefit of sotorasib in patients with active, previously untreated brain metastases in KRAS G12C-mutated NSCLC.

Keywords: KRAS inhibition; KRAS-mutated NSCLC; NSCLC with active brain metastases.

Publication types

Case Reports